Influence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: a pilot study

Página do item simplificado
dc.contributor.authorNogueira Júnior, Roberto Cesar [UNIFESP]
dc.contributor.authorCosta, Ana Maria Massad [UNIFESP]
dc.contributor.authorSilva, Ismael Dale Cotrim Guerreiro da [UNIFESP]
dc.contributor.authorCarvalho, Cristina Valletta de [UNIFESP]
dc.contributor.authorMaganhin, Carla Cristina [UNIFESP]
dc.contributor.authorBaracat, Edmund Chada [UNIFESP]
dc.contributor.authorSoares Júnior, José Maria [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2016-01-24T14:17:19Z
dc.date.available2016-01-24T14:17:19Z
dc.date.issued2011-10-01
dc.description.abstractObjective To evaluate the influence of CYP17 polymorphism on menopausal symptoms after estrogen treatment.Methods A total of 130 women were recruited, but only 100 of these were selected according to inclusion and exclusion criteria; they were treated with 0.3 mg/day conjugated equine estrogens. One year later, the study was completed by 71 women. the analysis of the Kupperman menopausal index symptoms was made with information provided by the patients on daily diary cards. Blood samples were analyzed and the women were divided into two groups based on the CYP17, 5'-untranslated region: group A (wild-type homozygote and heterozygote) and group B (mutated homozygote).Results the values for the Kupperman menopausal index were similar in both groups at baseline. the symptoms in both groups decreased after 1 year of treatment when compared to those at baseline. the improvement rate was approximately 27.09% and 32.18%, in groups A and B, respectively. the levels of estrogen after treatment were higher in both groups in comparison with the baseline values. the testosterone level rose in group B with the 1-year treatment (0.48 +/- 0.16 ng/ml), reaching a higher level than the level in group A after treatment. the sex hormone binding globulin (SHBG) level showed a significant increase after the 1-year treatment in group B, surpassing both the baseline and the after-treatment values in group A (p < 0.01).Conclusion Our data suggest that the CYP17 polymorphism did not influence the action of estrogen on menopause symptoms during the 1-year treatment. the extra production of estrogen and androgen may have been countered by the elevation of SHBG levels.en
dc.description.affiliationUniversidade Federal de São Paulo, BR-04021051 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Gynecol, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Obstet & Gynecol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, BR-04021051 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Gynecol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)pt
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt
dc.format.extent537-543
dc.identifierhttps://dx.doi.org/10.3109/13697137.2010.548668
dc.identifier.citationClimacteric. London: Informa Healthcare, v. 14, n. 5, p. 537-543, 2011.
dc.identifier.doi10.3109/13697137.2010.548668
dc.identifier.issn1369-7137
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/34136
dc.identifier.wosWOS:000294827100005
dc.language.isoeng
dc.publisherInforma Healthcare
dc.relation.ispartofClimacteric
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dc.subjectPolymorphismen
dc.subjectCYP17en
dc.subjectEstrogenen
dc.subjectHot flushesen
dc.titleInfluence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: a pilot studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos